Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicenter, Phase II Study of Elranatamab as Single Agent for the Treatment of Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes (GEM-RANTAB)

NCT06282978 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT06282978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06282978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicenter, Phase II Study of Elranatamab as Single Agent for the Treatment of Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes (GEM-RANTAB)
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 23, 2023
Completion date
December 31, 2029
Enrollment
50 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma in relapse